Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or OpenAthens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Current Concepts in Movement Disorder Management

Editor(s): Niranjan A. (Pittsburgh, PA) 
Lunsford L.D. (Pittsburgh, PA) 
Richardson R.M. (Pittsburgh, PA) 
Cover

Gene Therapy for Parkinson's Disease

Sudhakar V. · Richardson R.M.

Author affiliations

Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA

Related Articles for ""

Niranjan A, Lunsford LD, Richardson RM (eds): Current Concepts in Movement Disorder Management. Prog Neurol Surg. Basel, Karger, 2018, vol 33, pp 253-264

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Complete book

  • Immediate access to all parts of this book
  • Cover-to-cover formats may be available
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restriction for personal use
read more

Pricing depends on hard-cover price


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of  

Published online: January 12, 2018
Cover Date: 2018

Number of Print Pages: 12
Number of Figures: 3
Number of Tables: 0

ISBN: 978-3-318-06201-4 (Print)
eISBN: 978-3-318-06202-1 (Online)

Abstract

Gene therapy is a clinical tool that may eventually provide therapeutic benefit to patients suffering from movement disorders through a few potential mechanisms: direct correction of the pathogenic mechanism, neuroprotection, neurorestoration or symptom control. The therapeutic mechanism is therefore dependent on knowledge of disease pathogenesis and the required temporal and spatial specificities of gene expression. An additional critical challenge is achieving the most complete transduction of the target structure while avoiding leakage into neighboring regions or perivascular spaces. Although critical clinical work is ongoing to optimize the direct intracerebral delivery of transgenes to the brain, the field has recently entered a new technological era, where interventional-MRI-guided convection-enhanced delivery is the gold standard for verifying accurate vector delivery in real-time.

© 2018 S. Karger AG, Basel


References

  1. Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, et al: Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9:581-591.
  2. Castrioto A, Lozano AM, Poon YY, Lang AE, Fallis M, Moro E: Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol 2011;68:1550-1556.
  3. Fasano A, Romito LM, Daniele A, Piano C, Zinno M, Bentivoglio AR, et al: Motor and cognitive outcome in patients with Parkinson's disease 8 years after subthalamic implants. Brain 2010;133:2664-2676.
  4. Richardson RM, Varenika V, Forsayeth JR, Bankiewicz KS: Future applications: gene therapy. Neurosurg Clin N Am 2009;20:205-210.
  5. Bingaman KD, Bakay RA: The primate model of Parkinson's disease: Its usefulness, limitations, and importance in directing future studies. Prog in Brain Res 2000;127:267-297.
  6. Richardson RM, Larson PS, Bankiewicz KS: Gene and cell delivery to the degenerated striatum: status of preclinical efforts in primate models. Neurosurgery 2008;63:629-642.
  7. Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999;22:391-397.
  8. Cenci MA, Whishaw IQ, Schallert T: Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 2002;3:574-579.
  9. Langston JW, Ballard P, Tetrud JW, Irwin I: Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
  10. Soderstrom K, O'Malley J, Steece-Collier K, Kordower JH: Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant 2006;15:251-265.
  11. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, et al: The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 2001;76:1265-1274.
  12. Bankiewicz KS, Oldfield EH, Chiueh CC, Doppman JL, Jacobowitz DM, Kopin IJ: Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 1986;39:7-16.
  13. Eberling JL, Jagust WJ, Taylor S, Bringas J, Pivirotto P, VanBrocklin HF, et al: A novel MPTP primate model of Parkinson's disease: neurochemical and clinical changes. Brain Res 1998;805:259-262.
  14. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins R, et al: Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009;73:1662-1669.
  15. Eberling JL, Jagust WJ, Christine CW, Starr P, Larson P, Bankiewicz KS, et al: Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 2008;70:1980-1983.
  16. Muramatsu S, Fujimoto K, Kato S, Mizukami H, Asari S, Ikeguchi K, et al: A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol Ther 2010;18:1731-1735.
  17. Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, et al: Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008;7:400-408.
  18. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al: Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:1164-1172.
  19. LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, et al: AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial. Lancet Neurol 2011;10:309-319.
  20. Kells AP, Hadaczek P, Yin D, Bringas J, Varenika V, Forsayeth J, et al: Efficient gene therapy-based method for the delivery of therapeutics to primate cortex. Proc Natl Acad Sci USA 2009;106:2407-2411.
  21. Palfi S, Gurruchaga JM, Ralph GS, Lepetit H, Lavisse S, Buttery PC, et al: Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 2014;383:1138-1146.
  22. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994;91:2076-2080.
  23. Krauze MT, Saito R, Noble C, Tamas M, Bringas J, Park JW, et al: Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 2005;103:923-929.
  24. Varenika V, Kells AP, Valles F, Hadaczek P, Forsayeth J, Bankiewicz KS: Controlled dissemination of AAV vectors in the primate brain. Pro Brain Res 2009;175:163-172.
  25. Valles F, Fiandaca MS, Bringas J, Dickinson P, LeCouteur R, Higgins R, et al: Anatomic compression caused by high-volume convection-enhanced delivery to the brain. Neurosurgery 2009;65:579-585.
  26. Valles F, Fiandaca MS, Eberling JL, Starr PA, Larson PS, Christine CW, et al: Qualitative imaging of adeno-associated virus serotype 2-human aromatic L-amino acid decarboxylase gene therapy in a phase i study for the treatment of Parkinson disease. Neurosurgery 2010;67:1377-1385.
  27. Varenika V, Dickinson P, Bringas J, LeCouteur R, Higgins R, Park J, et al: Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg 2008;109:874-880.
  28. Richardson RM, Gimenez F, Salegio EA, Su X, Bringas J, Berger MS, et al: T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery. Neurosurgery 2011;69:154-163.
  29. Richardson RM, Kells AP, Martin AJ, Larson PS, Starr PA, Piferi PG, et al: Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain. Stereotact Funct Neurosurg 2011;89:141-151.
  30. Richardson RM, Kells AP, Rosenbluth KH, Salegio EA, Fiandaca MS, Larson PS, et al: Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther 2011;19:1048-1057.
  31. Yin D, Richardson RM, Fiandaca MS, Bringas J, Forsayeth J, Berger MS, et al: Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics. J Neurosurg 2010;113:240-248.
  32. Yin D, Valles FE, Fiandaca MS, Bringas J, Gimenez F, Berger MS, et al: Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage 2011;54(suppl 1):S196-S203.
  33. Su X, Kells AP, Salegio AE, Richardson RM, Hadaczek P, Beyer J, et al: Real-time MR imaging with Gadoteridol predicts distribution of transgenes after convection-enhanced delivery of AAV2 vectors. Mol Ther 2010;18:1490-1495.
  34. Levy R, Lang AE, Dostrovsky JO, Pahapill P, Romas J, Saint-Cyr J, et al: Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms. Brain 2001;124:2105-2118.
  35. Emborg ME, Carbon M, Holden JE, During MJ, Ma Y, Tang C, et al: Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 2007;27:501-509.
  36. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, et al: Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 2007;369:2097-2105.
  37. Bankiewicz KS, Forsayeth J, Eberling JL, Sanchez-Pernaute R, Pivirotto P, Bringas J, et al: Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 2006;14:564-570.
  38. Hadaczek P, Eberling JL, Pivirotto P, Bringas J, Forsayeth J, Bankiewicz KS: Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC. Mol Ther 2010;18:1458-1461.
  39. Forsayeth JR, Eberling JL, Sanftner LM, Zhen Z, Pivirotto P, Bringas J, et al: A dose-ranging study of AAV-hAADC therapy in parkinsonian monkeys. Mol Ther 2006;14:571-577.
  40. San Sebastian W, Richardson RM, Kells AP, Lamarre C, Bringas J, Pivirotto P, et al: Safety and tolerability of magnetic resonance imaging-guided convection-enhanced delivery of AAV2-hAADC with a novel delivery platform in nonhuman primate striatum. Hum Gene Ther 2012;23:210-217.
  41. Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, et al: Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000;164:2-14.
  42. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, et al: Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 2009;73:1662-1669.
  43. Mittermeyer G, Christine CW, Rosenbluth KH, Baker SL, Starr P, Larson P, et al: Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Hum Gene Ther 2012;23:377-381.
  44. Dass B, Olanow CW, Kordower JH: Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology 2006;66(10 suppl 4):S89-S103.
  45. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, et al: Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000;290:767-773.
  46. Johnston LC, Eberling J, Pivirotto P, Hadaczek P, Federoff HJ, Forsayeth J, et al: Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys. Hum Gene Ther 2009;20:497-510.
  47. Su X, Kells AP, Huang EJ, Lee HS, Hadaczek P, Beyer J, et al: Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 2009;20:1627-1640.
  48. Kells AP, Eberling J, Su X, Pivirotto P, Bringas J, Hadaczek P, et al: Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 2010;30:9567-9577.
  49. Richardson RM, Kells AP, Rosenbluth KH, Salegio EA, Fiandaca MS, Larson PS, et al: Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther 2011;19:1048-1057.
  50. Cik M, Masure S, Lesage AS, Van Der Linden I, Van Gompel P, Pangalos MN, et al: Binding of GDNF and Neurturin to Human GDNF family receptor alpha 1 and 2. Influence of cRET and cooperative interactions. J Biol Chem 2000;275:27505-27512.
  51. Kordower JH, Herzog CD, Dass B, Bakay RA, Stansell J 3rd, Gasmi M, et al: Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006;60:706-715.
  52. Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, et al: Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol 2015;78:248-257.
  53. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al: Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2010;9:1164-1172.
  54. Bartus RT, Baumann TL, Siffert J, Herzog CD, Alterman R, Boulis N, et al: Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013;80:1698-1701.
  55. Warren Olanow C, Bartus RT, Baumann TL, Factor S, Boulis N, Stacy M, et al: Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: a double-blind, randomized, controlled trial. Ann Neurol 2015;78:248-257.

Article / Publication Details

First-Page Preview
Abstract of  

Published online: January 12, 2018
Cover Date: 2018

Number of Print Pages: 12
Number of Figures: 3
Number of Tables: 0

ISBN: 978-3-318-06201-4 (Print)
eISBN: 978-3-318-06202-1 (Online)


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.